Search results for "cut"

showing 10 items of 5063 documents

Immunomodulatory and Hematopoietic Effects of Recombinant Human Interleukin-6 in Patients with Advanced Renal Cell Cancer

1996

Interleukin-6 (IL-6) is a cytokine with pleiotropic biologic activities on B cells, T cells, and hematopoietic progenitors. The present study was undertaken to assess pharmacodynamic effects of subcutaneous administration of IL-6 on blood counts, immunologic parameters, and acute-phase reactants. Blood samples were taken from patients with advanced renal cell cancer participating in a phase II trial of recombinant human IL-6. Multiparameter FACS analyses of peripheral blood mononuclear cells were performed using antibodies against CD3, CD4, CD8, HLA-DR, CD56, CD28, CD38, CD19, sIgM, and sIgG. Serum levels of IL-10, soluble CD23 (sCD23), sCD25, IL-1 receptor antagonist protein (IL-1RA), solu…

medicine.medical_specialtyInjections Subcutaneousmedicine.medical_treatmentImmunologyPeripheral blood mononuclear cellCD19chemistry.chemical_compoundImmunophenotypingAdjuvants ImmunologicVirologyInternal medicinemedicineHumansAcute-Phase ReactionCarcinoma Renal CellbiologyInterleukin-6business.industryCD23NeopterinCell BiologyKidney NeoplasmsRecombinant ProteinsBlood Cell CountHematopoiesisHaematopoiesisCytokineEndocrinologychemistryImmunologybiology.proteinbusinessCD8Journal of Interferon & Cytokine Research
researchProduct

Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocy…

2018

Relapse of acute leukemia (AL) after allogeneic hematopoietic cell transplantation (Allo-HCT) entails a dismal prognosis. In this scenario, donor lymphocyte infusions (DLIs) and second Allo-HCT are two major approaches. We compared outcomes of AL patients treated for relapse with DLI or second Allo-HCT after receiving debulking therapy. In total, 46 patients were included in the study; 30 (65%) had acute myeloid leukemia and 16 (35%) had acute lymphoblastic leukemia. The median age was 38 years (range 4-66). Twenty-seven patients received a second Allo-HCT and 19 patients received DLI. The median follow-up of the cohort was 273 days (range 9-7013). Overall survival (OS), disease-free surviv…

OncologyMaleCancer ResearchTransplantation Conditioningmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationKaplan-Meier EstimateCohort Studies0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceChildAcute leukemiaUnivariate analysisHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsLeukemiaLeukemia Myeloid Acutesurgical procedures operative030220 oncology & carcinogenesisChild PreschoolLymphocyte TransfusionFemaleLeukocyte Reduction ProceduresAdultmedicine.medical_specialtyAdolescentGraft vs Leukemia EffectDisease-Free Survival03 medical and health sciencesYoung AdultInternal medicineGeneticsmedicineHumansMolecular BiologyAgedRetrospective StudiesImmunosuppression TherapySalvage Therapybusiness.industryCell Biologymedicine.diseaseTransplantationbusiness030215 immunologyExperimental hematology
researchProduct

EpCAM and microvascular obstruction in patients with STEMI: a cardiac magnetic resonance study

2020

Abstract Introduction and objectives Microvascular obstruction (MVO) is negatively associated with cardiac structure and worse prognosis after ST-segment elevation myocardial infarction (STEMI). Epithelial cell adhesion molecule (EpCAM), involved in epithelium adhesion, is an understudied area in the MVO setting. We aimed to determine whether EpCAM is associated with the appearance of cardiac magnetic resonance (CMR)-derived MVO and long-term systolic function in reperfused STEMI. Methods We prospectively included 106 patients with a first STEMI treated with percutaneous coronary intervention, quantifying serum levels of EpCAM 24 hours postreperfusion. All patients underwent CMR imaging 1 w…

Malemedicine.medical_specialtyMagnetic Resonance Spectroscopymedicine.medical_treatmentMagnetic Resonance Imaging Cine030204 cardiovascular system & hematologyVentricular Function Left03 medical and health scienceschemistry.chemical_compoundPercutaneous Coronary Intervention0302 clinical medicineInternal medicinemedicineHumansIn patientcardiovascular diseasesMyocardial infarctionVentricular remodelingEnd-systolic volumeAgedEjection fractionbusiness.industryMicrocirculationPercutaneous coronary interventionStroke VolumeEpithelial cell adhesion moleculeGeneral MedicineMiddle AgedEpithelial Cell Adhesion Moleculemedicine.diseaseMagnetic Resonance ImagingchemistryCardiologyST Elevation Myocardial InfarctionFemalebusinessCardiac magnetic resonancehuman activitiesRevista Española de Cardiología (English Edition)
researchProduct

Cecal trap: CT findings of isolated cecal necrosis

2016

Learning objectives Background Findings and procedure details Conclusion Personal information References

genetic structuresGastrointestinal tractIschaemia / InfarctioneducationAbdomenEmergencyCT cecal necrosisAcuteContrast agent-intravenousSettore MED/36 - Diagnostica Per Immagini E RadioterapiaCT
researchProduct

Minimal clinically important difference and minimal detectable change of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0…

2020

Objectives: The aim of this study is to estimate a minimal clinically important difference (MCID) and a minimal detectable change (MDC) of the 12-item WHODAS 2.0 amongst patients with chronic musculoskeletal pain. Design: Cross-sectional cohort study. Setting: Outpatient Physical and Rehabilitation Medicine clinic. Subjects: A total of 1988 consecutive patients with musculoskeletal pain. Interventions: A distribution-based approach was employed to estimate a minimal clinically important difference, a minimal detectable change, and a minimal detectable percent change (MDC%). Results: The mean age of the patients was 48 years, and 65% were women. The average intensity of pain was 6,3 (2.0) po…

MaleMusculoskeletal painSchedule2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)WHODASPhysical Therapy Sports Therapy and Rehabilitationminimal detectable changetuki- ja liikuntaelimetWorld healthDisability assessmentCohort StudiesDisability EvaluationMusculoskeletal PainHumansMedicineskin and connective tissue diseasesmusculoskeletal painPain Measurementbusiness.industryMinimal clinically important differenceminimal clinically important differenceRehabilitationkipuMiddle AgedCross-Sectional StudiesPhysical therapyFemalesense organsWhodasChronic PainbusinessData Collection toolsClinical Rehabilitation
researchProduct

Hemodynamic Parameters Change Earlier Than Tissue Oxygen Tension in Hemorrhage

2010

BACKGROUND: Untreated hypovolemia results in impaired outcome. This study tests our hypothesis whether general hemodynamic parameters detect acute blood loss earlier than monitoring parameters of regional tissue beds. MATERIALS AND METHODS: Eight pigs (23-25 kg) were anesthetized and mechanically ventilated. A pulmonary artery catheter and an arterial catheter were inserted. Tissue oxygen tension was measured with Clark-type electrodes in the jejunal and colonic wall, in the liver, and subcutaneously. Jejunal microcirculation was assessed by laser Doppler flowmetry (LDF). Intravascular volume was optimized using difference in pulse pressure (dPP) to keep dPP below 13%. Sixty minutes after p…

Cardiac outputMean arterial pressureColonHypovolemiaSus scrofaHemodynamicsBlood PressureHemorrhageBlood volumeHypovolemiaLaser-Doppler FlowmetryIntravascular volume statusmedicineAnimalsCardiac OutputPulmonary wedge pressureBlood Volumebusiness.industryMicrocirculationHemodynamicsBlood flowHeart ArrestOxygenDisease Models AnimalJejunumLiverAnesthesiaAcute DiseaseSurgerymedicine.symptombusinessJournal of Surgical Research
researchProduct

Association between Serum Heat Shock Proteins and Gamma-Delta T Cells—An Outdated Clue or a New Direction in Searching for an Anticancer Strategy? A …

2021

HSPs demonstrate a strong association with gamma-delta (γδ) T cells. Most of the studies regarding interactions between the parameters were conducted in the 1990s. Despite promising results, the concept of targeting γδ T cells by HSPs seems to be a forgotten direction due to potent non-peptidic phosphoantigens rather than HSPs have been found to be the essential stimulatory components for human γδ cells. Currently, with greater knowledge of lymphocyte diversity, and more accurate diagnostic methods, we decided to study the correlation once again in the neoplastic condition. Twenty-one children with newly diagnosed acute lymphoblastic leukaemia (ALL) were enrolled on the study. Serum HSP90 c…

Technologyacute lymphoblastic leukaemiaQH301-705.5LymphocyteCD3QC1-999Human leukocyte antigenBiologyFlow cytometryHeat shock proteinmedicineGeneral Materials ScienceBiology (General)InstrumentationChildhood allQD1-999Fluid Flow and Transfer Processesmedicine.diagnostic_testAcute lymphoblastic leukaemia Gamma-delta T cells Serum HSP90Process Chemistry and Technologyserum HSP90TPhysicsGeneral Engineeringgamma-delta T cellsEngineering (General). Civil engineering (General)Hsp90Computer Science ApplicationsChemistrymedicine.anatomical_structureImmunologybiology.proteinTA1-2040CD8Applied Sciences
researchProduct

SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients

2020

Background The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity. Patients and methods This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers wer…

0301 basic medicineMaleAntibodies ViralSeverity of Illness IndexGastroenterologylaw.invention0302 clinical medicinelaw030212 general & internal medicinebiologyInflammatory biomarkersMiddle AgedIntensive care unitHospitalizationTiterInfectious DiseasesSpike Glycoprotein CoronavirusFemaleAntibodyCoronavirus InfectionsAdultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyPneumonia ViralNeutralizing antibodiesArticleVirus03 medical and health sciencesBetacoronavirusYoung AdultVirologyInternal medicineSeverity of illnessmedicineHumansPandemicsAgedRetrospective StudiesInflammationbusiness.industrySARS-CoV-2C-reactive proteinCOVID-19Retrospective cohort studyAntibodies NeutralizingFerritinbiology.proteinBinding Sites AntibodybusinessBiomarkers
researchProduct

Synthesis and Pharmacological Activities of Novel 3-(Isoxazol-3-yl)-quinazolin-4(3H)-one Derivatives

1999

Several new 3-(isoxazol-3-yl)-quinazolin-4(3H)-one derivatives were synthesized and tested for their analgesic and antiinflammatory activities, as well as for their acute toxicity and ulcerogenic effect. A few compounds were as active as phenylbutazone in the writhing and acetic acid peritonitis tests. They had a very low ulcerogenic effect.

MaleStereochemistryAnalgesicAnti-Inflammatory AgentsPharmaceutical ScienceChemical synthesisRats Sprague-DawleyMiceStructure-Activity Relationshipchemistry.chemical_compoundAcetic acidDrug DiscoveryPhenylbutazonemedicineAnimalsStomach UlcerNuclear Magnetic Resonance BiomolecularAnalgesicsBehavior AnimalBicyclic moleculeAcute toxicityRatschemistryToxicityQuinazolinesLactammedicine.drugArchiv der Pharmazie
researchProduct

Editorial: The Challenge of New Therapeutic Approaches for Unmet Therapeutic Needs

2020

Pharmacologydrug-designmedicine.medical_specialty2019-20 coronavirus outbreakdrug-design; efficacy/risk ratio; innovative therapies; pharmaceutical innovations; pharmacology innovationCoronavirus disease 2019 (COVID-19)business.industrypharmacology innovationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)lcsh:RM1-950lcsh:Therapeutics. PharmacologyInnovative Therapiesinnovative therapiespharmaceutical innovationsmedicinePharmacology (medical)Intensive care medicinebusinessPharmaceutical innovationsefficacy/risk ratio
researchProduct